Alexion Pharmaceuticals FCF yield
What is the FCF yield of Alexion Pharmaceuticals?
The FCF yield of Alexion Pharmaceuticals Inc. is 7.38%
What is the definition of FCF yield?
Free cash flow yield (FCF yield) is a financial ratio that compares the free cash flow per share to the market value per share. The ratio is calculated by dividing free cash flow per share by the current share price.
ttm (trailing twelve months)
Free cash flow yield is a good measure of the company’s cash flow in respect to the company’s size. Larger companies tend to have a higher cash flow yield, but it’s not always the case. The higher the free cash flow yield, the more cash the company is generating that can be quickly accessed to satisfy its obligations. The lower the free cash flow yield, the more money investors are putting into the company with little result. The higher the ratio, the more attractive the investment is as it suggests that investors are paying less for each unit of free cash flow.
Free cash flow acts as an indicator of how capable a company is of repaying all of its obligations. It is a solid indicator of how financially stable a company is. It is calculated as:
Free cash flow yield = Free cash flow per share / market price per share
FCF yield of companies in the Health Care sector on NASDAQ compared to Alexion Pharmaceuticals
What does Alexion Pharmaceuticals do?
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Companies with fcf yield similar to Alexion Pharmaceuticals
- Lucas Bols NV has FCF yield of 7.36%
- WH (HK) has FCF yield of 7.37%
- NexPoint Real Estate Finance Inc has FCF yield of 7.37%
- Terex has FCF yield of 7.37%
- SS&C Technologies Inc has FCF yield of 7.37%
- Lundin Mining has FCF yield of 7.37%
- Alexion Pharmaceuticals has FCF yield of 7.38%
- NamSys has FCF yield of 7.38%
- EVI Industries Inc has FCF yield of 7.39%
- First Seacoast Bancorp has FCF yield of 7.39%
- Frey SA has FCF yield of 7.39%
- Teleperformance SE has FCF yield of 7.39%
- Ryanair Plc has FCF yield of 7.39%